IL2 and chronic graft versus host disease: GVHD prophylaxis using calcineurin inhibitors (cyclosporin or tacrolimus) reduce the expansion of effector T cells (Teff) by blocking IL-2 and prevent acute GVHD, but fail to reduce chronic GVHD (58–60).